Opinion|Videos|June 9, 2025
Future Perspectives in cGVHD
Panelists discuss how future directions in chronic graft-vs-host disease (cGVHD) management may include preemptive use of targeted therapies, first-line treatment with newer agents, and cell-based approaches.
Advertisement
Episodes in this series
Future Directions
For therapy sequencing, approaches varied:
- Dr Shaughnessy: Generally switching between agents with brief steroid pulse
- Dr Bishop: Adding new agents to maintain control from multiple mechanisms
- Dr Lee: Cautious about combining without safety data, preferring switching
Future directions the panel is excited about:
- Moving targeted agents to first-line therapy
- Cell therapies for cGVHD (mesenchymal stromal cells as precedent from pediatric acute GVHD)
- Combination therapies in single molecules (eg, ROCK/JAK inhibitor)
- Agents targeting cell migration
Key principles for treatment goals:
- Symptom control and quality of life improvement
- Getting patients off steroids
- Disease stabilization, especially for lung involvement
- Tailoring therapy to organ involvement and tolerability
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
Theodore Wagener, PhD, of Ohio State discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
"AI will not replace oncologists; it will help interpret complex data and design more precise, adaptive, personalized cancer treatment," the authors write.
The phase 2 NRG-BR002 failed to improve outcomes with targeted radiotherapy to oligometastases; the phase 3 portion will not proceed.
ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.
VIR-5500 and [²¹²Pb]PSV359 received FDA fast track designations for prostate cancer and solitary fibrous tumors, respectively.
The approval of the adjuvant atezolizumab combination in dMMR colon cancer is supported by the phase 3 ATOMIC trial.
During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia whose quality of life is impaired even as her platelet count recovers.
Pan-cancer study shows age-based germline testing misses most inherited cancer variants, supporting broader genetic screening to guide treatment and family risk.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
CLL Treatment Enters a New Era of Targeted Combinations
2
Psilocybin-Assisted Therapy Aims at Existential Distress in Lung Cancer
3
SurVaxM Improves OS Only in Younger Subgroup in Newly Diagnosed Glioblastoma
4
AI in Precision Oncology: A Paradigm Shift
5